Unknown

Dataset Information

0

Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).


ABSTRACT: Paclitaxel, an anti-microtubule agent, is an effective chemotherapeutic drug in breast cancer. Nonetheless, resistance to paclitaxel remains a major clinical challenge. The need to better understand the resistant phenotype and to find biomarkers that could predict tumor response to paclitaxel is evident. In estrogen receptor ?-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to low dose paclitaxel (10 nM). However, two variants of CAV1 exist: the full-length form, CAV1? (wild-type CAV1 or wtCAV1), and a truncated form, CAV1?. Only wtCAV1 has the Tyr-14 region at the N terminus. The precise cellular functions of CAV1 variants are unknown. We now show that CAV1 variants play distinct roles in paclitaxel-mediated cell death/survival. CAV1? expression is increased in paclitaxel-resistant cells when compared with sensitive cells. Expression of CAV1? in sensitive cells significantly reduces their responsiveness to paclitaxel. These activities reflect an essential role for Tyr-14 phosphorylation because wtCAV1 expression, but not a phosphorylation-deficient mutant (Y14F), inactivates BCL2 and BCLxL through activation of c-Jun N-terminal kinase (JNK). MCF-7 cells that express Y14F are resistant to paclitaxel and are resensitized by co-treatment with ABT-737, a BH3-mimetic small molecule inhibitor. Using structural homology modeling, we propose that phosphorylation on Tyr-14 enables a favorable conformation for proteins to bind to the CAV1 scaffolding domain. Thus, we highlight novel roles for CAV1 variants in cell death; wtCAV1 promotes cell death, whereas CAV1? promotes cell survival by preventing inactivation of BCL2 and BCLxL via JNK in paclitaxel-mediated apoptosis.

SUBMITTER: Shajahan AN 

PROVIDER: S-EPMC3366801 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

Shajahan Ayesha N AN   Dobbin Zachary C ZC   Hickman F Edward FE   Dakshanamurthy Sivanesan S   Clarke Robert R  

The Journal of biological chemistry 20120320 21


Paclitaxel, an anti-microtubule agent, is an effective chemotherapeutic drug in breast cancer. Nonetheless, resistance to paclitaxel remains a major clinical challenge. The need to better understand the resistant phenotype and to find biomarkers that could predict tumor response to paclitaxel is evident. In estrogen receptor α-positive (ER(+)) breast cancer cells, phosphorylation of caveolin-1 (CAV1) on Tyr-14 facilitates mitochondrial apoptosis by increasing BCL2 phosphorylation in response to  ...[more]

Similar Datasets

| S-EPMC6214713 | biostudies-literature
| S-EPMC4927282 | biostudies-literature
| S-EPMC2927421 | biostudies-literature
| S-EPMC7190567 | biostudies-literature
| S-EPMC3578034 | biostudies-literature
| S-EPMC2290850 | biostudies-other
| S-EPMC5130029 | biostudies-literature
| S-EPMC4223184 | biostudies-literature
| S-EPMC5541718 | biostudies-literature
| S-EPMC3323582 | biostudies-literature